Bio Holding News Today

Key Insights Tevogen Bio Holdings' significant insider ownership suggests inherent interests in company's expansion...

Virtu Financial LLC purchased a new stake in VectivBio Holding AG (NASDAQ:VECT – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 41,411 shares of the company’s stock, valued at approximately $699,000. Other hedge funds have also made changes to […]

NEW YORK, May 31, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning... | May 31, 2023

Tuesday May 23, 2023 Trading Desk: (312) 236-8907 TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Philly Fed; 9:45ET S&P Global US Manufacturing PMI, Services PMI; 10:00ET New Home Sales, Richmond Fed Manufacturing Index Fed Chair Powell will be attending the New Democrat Coalition today to discuss the debt

Investment Analysts’ upgrades for Friday, June 3rd: ABC-Mart,Inc. (OTCMKTS:AMKYF) was upgraded by analysts at Daiwa Capital Markets from a neutral rating to an outperform rating. Brenntag (OTCMKTS:BNTGY) was upgraded by analysts at Baader Bank to a buy rating. Ciena (NYSE:CIEN) was upgraded by analysts at B. Riley from a neutral rating to a buy rating. […]

VectivBio (NASDAQ:VECT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments […]

VectivBio (NASDAQ:VECT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for […]

VectivBio (NASDAQ:VECT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare […]

VectivBio (NASDAQ:VECT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments […]

VectivBio (NASDAQ:VECT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe […]